ClinicalTrials.gov
ClinicalTrials.gov Menu

Fatty Acid Quality and Overweight (FO-study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01034436
Recruitment Status : Completed
First Posted : December 17, 2009
Last Update Posted : June 18, 2015
Sponsor:
Information provided by (Responsible Party):
Stine Marie Ulven, Oslo and Akershus University College of Applied Sciences

Brief Summary:
The purpose of this study is to study the health effects of fatty acid quality in healthy, overweight individuals.

Condition or disease Intervention/treatment Phase
Weight Reduction and Insulin Sensitivity Dietary Supplement: fatty acid quality and overweight Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Fatty Acid Quality and Overweight
Study Start Date : February 2009
Actual Primary Completion Date : June 2009

Arm Intervention/treatment
Placebo Comparator: Low intake of ALA and triacylglycerols
Sunflower oil
Dietary Supplement: fatty acid quality and overweight
Duration 12 weeks

Experimental: high intake of ALA and triacylglyceroles
Canola and linseed oils
Dietary Supplement: fatty acid quality and overweight
Duration 12 weeks

Experimental: high intake of ALA and diacylglycerols
Canola and linseed oils
Dietary Supplement: fatty acid quality and overweight
Duration 12 weeks




Primary Outcome Measures :
  1. Will intake of fat as diacylglycerols give weight reduction in overweight individuals? [ Time Frame: baseline (0 weeks), 12 weeks ]

Secondary Outcome Measures :
  1. Will a high intake of ALA involve reduced levels of inflammatory markers? [ Time Frame: baseline (0 weeks), 12 weeks ]
  2. Will a high intake of ALA involve changes in insulin sensitivity? [ Time Frame: baseline (0 weeks), 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • no use of medication, healthy, 27<BMI<40

Exclusion Criteria:

  • pregnant and lactating women, chronic diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01034436


Locations
Norway
Akershus University College
Oslo, Lillestrom, Norway, 2001
Sponsors and Collaborators
Oslo and Akershus University College of Applied Sciences
Investigators
Study Chair: Stine Marie Ulven, PhD University Hospital, Akershus

Responsible Party: Stine Marie Ulven, Associate professor, Oslo and Akershus University College of Applied Sciences
ClinicalTrials.gov Identifier: NCT01034436     History of Changes
Other Study ID Numbers: 6.2008.1368
First Posted: December 17, 2009    Key Record Dates
Last Update Posted: June 18, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Overweight
Insulin Resistance
Weight Loss
Body Weight
Signs and Symptoms
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Body Weight Changes